Intracellular and extracellular targets as mechanisms of cancer therapy by nanomaterials in relation to their physicochemical properties.
cancer therapy
cell death pathways
intracellular mechanisms
nanomaterial characteristics
nanomedicine
Journal
Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology
ISSN: 1939-0041
Titre abrégé: Wiley Interdiscip Rev Nanomed Nanobiotechnol
Pays: United States
ID NLM: 101508311
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
16
05
2020
revised:
08
10
2020
accepted:
13
10
2020
pubmed:
29
10
2020
medline:
5
11
2021
entrez:
28
10
2020
Statut:
ppublish
Résumé
Cancer nanomedicine has evolved in recent years and is only expected to increase due to the ease with which nanomaterials (NMs) may be manipulated to the advantage of the cancer patient. The success of nanomedicine is dependent on the cell death mechanism, which in turn is dependent on the organelle initially targeted. The success of cancer nanomedicine is also dependent on other cellular mechanisms such as the induction of autophagy dysfunction, manipulation of the tumor microenvironment (TME) and secretome or induction of host immune responses. Current cancer phototherapies for example, photothermal- or photodynamic therapies as well as radio enhancement also form a major part of cancer nanomedicine. In general, cancer nanomedicine may be grouped into those NMs exhibiting inherent anti-cancer properties that is, self-therapeutic NMs (Group 1), NMs leading to localization of phototherapies or radio-enhancement (Group 2), and NMs as nanocarriers in the absence or presence of external radiation (Group 3). The recent advances of these three groups, together with their advantages and disadvantages as well as their cellular mechanisms and ultimate outcomes are summarized in this review. By exploiting these different intracellular mechanisms involved in initiating cell death pathways, it is possible to synthesize NMs that may have the desirable characteristics to maximize their efficacy in cancer therapy. Therefore, a summary of these important physicochemical characteristics is also presented that need to be considered for optimal cancer cell targeting and initiation of mechanisms that will lead to cancerous cell death. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease Toxicology and Regulatory Issues in Nanomedicine > Toxicology of Nanomaterials Toxicology and Regulatory Issues in Nanomedicine > Regulatory and Policy Issues in Nanomedicine.
Identifiants
pubmed: 33111484
doi: 10.1002/wnan.1680
pmc: PMC7988657
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1680Informations de copyright
© 2020 The Authors. WIREs Nanomedicine and Nanobiotechnology published by Wiley Periodicals LLC.
Références
PLoS One. 2013;8(1):e54578
pubmed: 23382918
Drug Des Devel Ther. 2013 Jul 17;7:585-99
pubmed: 23898223
Signal Transduct Target Ther. 2019 Sep 6;4:28
pubmed: 31637008
Autophagy. 2018;14(7):1185-1200
pubmed: 29940794
J Control Release. 2013 Sep 10;170(2):242-51
pubmed: 23735572
Signal Transduct Target Ther. 2018 Mar 16;3:7
pubmed: 29560283
Nanoscale. 2018 Nov 29;10(46):21640-21647
pubmed: 30232481
Int J Mol Sci. 2019 Feb 22;20(4):
pubmed: 30813333
J Nanobiotechnology. 2019 Jan 22;17(1):9
pubmed: 30670028
Int J Mol Sci. 2017 Jan 14;18(1):
pubmed: 28098821
Adv Mater. 2017 Feb;29(7):
pubmed: 28009461
Nanomedicine. 2018 Apr;14(3):883-896
pubmed: 29366881
ACS Nano. 2018 Jun 26;12(6):6252-6262
pubmed: 29791136
Nat Nanotechnol. 2016 Nov;11(11):977-985
pubmed: 27668796
J Adv Res. 2018 Jun 25;15:1-18
pubmed: 30581608
Int J Nanomedicine. 2015 Aug 31;10:5505-12
pubmed: 26357474
Front Oncol. 2019 Sep 26;9:971
pubmed: 31616642
ACS Appl Mater Interfaces. 2017 May 17;9(19):15952-15961
pubmed: 28447447
J Am Chem Soc. 2010 Feb 10;132(5):1517-9
pubmed: 20085324
Nano Today. 2019 Aug;27:73-98
pubmed: 32292488
J Biol Chem. 2016 Jul 1;291(27):14170-14184
pubmed: 27226546
Sci Rep. 2016 Oct 04;6:34413
pubmed: 27698385
Clin Cancer Res. 2005 May 1;11(9):3530-4
pubmed: 15867256
ACS Appl Mater Interfaces. 2016 Sep 14;8(36):23498-508
pubmed: 27558413
ACS Nano. 2015 Jul 28;9(7):6861-71
pubmed: 26171764
In Vivo. 2007 Mar-Apr;21(2):215-26
pubmed: 17436569
J Am Chem Soc. 2018 Mar 21;140(11):4062-4070
pubmed: 29406728
Wei Sheng Yan Jiu. 2013 Mar;42(2):273-6
pubmed: 23654106
Oncotarget. 2017 Dec 23;9(11):9685-9705
pubmed: 29515763
Biomater Sci. 2018 Nov 20;6(12):3300-3308
pubmed: 30350829
ACS Appl Mater Interfaces. 2018 Jan 31;10(4):3449-3458
pubmed: 29318884
Mitochondrion. 2014 Nov;19 Pt A:49-57
pubmed: 24984038
Chem Sci. 2015 Mar;6(3):1832-1845
pubmed: 25709804
Colloids Surf B Biointerfaces. 2009 Oct 1;73(1):51-7
pubmed: 19481908
Nat Nanotechnol. 2010 Aug;5(8):602-6
pubmed: 20581833
Acta Biochim Biophys Sin (Shanghai). 2011 Apr;43(4):316-23
pubmed: 21377996
Nanotechnology. 2010 Feb 26;21(8):85103
pubmed: 20101074
Ann N Y Acad Sci. 2016 May;1371(1):45-54
pubmed: 26599426
ACS Nano. 2018 Jun 26;12(6):5197-5206
pubmed: 29894162
ACS Nano. 2012 Sep 25;6(9):7692-702
pubmed: 22870984
Proc Natl Acad Sci U S A. 2013 Apr 23;110(17):6700-5
pubmed: 23569259
Methods Mol Biol. 2010;624:25-37
pubmed: 20217587
Front Physiol. 2018 Jun 05;9:682
pubmed: 29922176
Biochem Pharmacol. 2014 Nov 1;92(1):112-30
pubmed: 25175739
Mutagenesis. 2017 Jan;32(1):203-213
pubmed: 27794034
Sci Rep. 2017 Feb 14;7:42591
pubmed: 28195184
ACS Nano. 2012 Apr 24;6(4):3318-26
pubmed: 22424173
Oncotarget. 2017 May 15;8(37):61083-61092
pubmed: 28977848
Biomater Sci. 2019 Mar 26;7(4):1311-1322
pubmed: 30734774
Toxicol Pathol. 2018 Jan;46(1):4-13
pubmed: 29034767
Acta Pharm Sin B. 2018 Oct;8(6):862-880
pubmed: 30505656
Cancer Nanotechnol. 2016;7(1):8
pubmed: 27867425
ACS Nano. 2018 Dec 26;12(12):12380-12392
pubmed: 30495919
J Control Release. 2013 Nov 28;172(1):330-340
pubmed: 24012486
ACS Nano. 2011 Nov 22;5(11):8629-39
pubmed: 21974862
Chem Soc Rev. 2018 Sep 17;47(18):6930-6946
pubmed: 30062349
Biomed Res Int. 2014;2014:179486
pubmed: 24963475
Int J Cell Biol. 2010;2010:170215
pubmed: 20169117
Proc Natl Acad Sci U S A. 2012 Oct 2;109(40):16288-93
pubmed: 22991470
Molecules. 2016 Mar 11;21(3):342
pubmed: 26978341
Nat Commun. 2019 Aug 23;10(1):3838
pubmed: 31444335
Nanomedicine. 2014 Jan;10(1):119-29
pubmed: 23891987
ACS Appl Mater Interfaces. 2017 Mar 1;9(8):6761-6771
pubmed: 28150943
Int J Nanomedicine. 2017 Sep 05;12:6537-6558
pubmed: 28919753
Biomaterials. 2012 Mar;33(7):2197-205
pubmed: 22177288
Nano Lett. 2010 May 12;10(5):1677-81
pubmed: 20369892
Int J Nanomedicine. 2017 Sep 05;12:6521-6535
pubmed: 28919752
Chem Commun (Camb). 2014 Aug 4;50(60):8117-20
pubmed: 24924212
Cancer Sci. 2008 Jul;99(7):1479-84
pubmed: 18410403
ACS Appl Mater Interfaces. 2018 Jun 20;10(24):20342-20355
pubmed: 29878757
ACS Nano. 2014 Jun 24;8(6):5852-62
pubmed: 24824865
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2021 Mar;13(2):e1680
pubmed: 33111484
Biomed Pharmacother. 2018 Oct;106:1098-1107
pubmed: 30119176
Nat Rev Mol Cell Biol. 2014 Mar;15(3):178-96
pubmed: 24556840
Angew Chem Int Ed Engl. 2012 Aug 27;51(35):8800-5
pubmed: 22847719
Vasc Health Risk Manag. 2006;2(3):213-9
pubmed: 17326328
Am J Cancer Res. 2017 May 01;7(5):1016-1036
pubmed: 28560055
Nanomedicine. 2011 Oct;7(5):580-7
pubmed: 21333757
Small. 2015 Mar 25;11(12):1453-1459
pubmed: 25354691
Nat Nanotechnol. 2020 Apr;15(4):331-341
pubmed: 32203435
Cancers (Basel). 2017 Dec 19;9(12):
pubmed: 29257070
Am J Transl Res. 2018 Aug 15;10(8):2306-2323
pubmed: 30210672
Adv Mater. 2018 Mar;30(12):e1704007
pubmed: 29356212
ACS Nano. 2016 Dec 27;10(12):10636-10651
pubmed: 27758098
Int J Nanomedicine. 2016 Aug 02;11:3655-75
pubmed: 27536105
Toxicol In Vitro. 2018 Feb;46:148-154
pubmed: 28987793
J Am Chem Soc. 2012 Apr 4;134(13):5722-5
pubmed: 22420312
Biomaterials. 2016 Dec;109:12-22
pubmed: 27639528
Bioconjug Chem. 2013 Jun 19;24(6):852-8
pubmed: 23682992
Ther Deliv. 2015 Mar;6(3):307-21
pubmed: 25853307
Bioconjug Chem. 2018 May 16;29(5):1659-1668
pubmed: 29526082
Biomaterials. 2009 Oct;30(31):6341-50
pubmed: 19698986
Small. 2011 Oct 4;7(19):2727-35
pubmed: 21861293
Molecules. 2018 Nov 18;23(11):
pubmed: 30453692
ACS Nano. 2014 Apr 22;8(4):3192-201
pubmed: 24597847
FEBS Lett. 2007 Mar 20;581(6):1157-60
pubmed: 17331505
Nano Lett. 2015 Jan 14;15(1):457-63
pubmed: 25479133
J Tissue Eng. 2019 Sep 17;10:2041731419877528
pubmed: 31555432
J Nanobiotechnology. 2007 May 08;5:4
pubmed: 17488514
Molecules. 2014 Sep 01;19(9):13498-508
pubmed: 25255752
Biomaterials. 2012 Apr;33(11):3235-42
pubmed: 22296829
Biomed Pharmacother. 2013 Sep;67(7):569-75
pubmed: 23786887
ACS Nano. 2010 May 25;4(5):2773-83
pubmed: 20429577
Nat Nanotechnol. 2016 Nov;11(11):986-994
pubmed: 27668795
Angew Chem Int Ed Engl. 2018 Aug 27;57(35):11198-11202
pubmed: 29905979
Traffic. 2018 Dec;19(12):918-931
pubmed: 30125440
Cancer Nanotechnol. 2017;8(1):2
pubmed: 28217176
Nanotechnology. 2011 Jul 15;22(28):285101
pubmed: 21654036
PLoS One. 2013 Jul 23;8(7):e69073
pubmed: 23935927
Cancer Cell. 2019 Jun 10;35(6):830-849
pubmed: 31105042
Mol Pharm. 2016 Jul 5;13(7):2578-87
pubmed: 27287467
J Phys Chem B. 2008 Aug 14;112(32):10005-11
pubmed: 18582008
Chem Soc Rev. 2020 Jul 21;49(14):5008-5057
pubmed: 32538379
ACS Nano. 2018 Nov 27;12(11):11355-11365
pubmed: 30375848
Nanotechnology. 2009 Sep 16;20(37):375101
pubmed: 19706948
Am J Cancer Res. 2018 Nov 01;8(11):2165-2175
pubmed: 30555736
J Pharm Pharmacol. 2008 Aug;60(8):977-85
pubmed: 18644191
Small. 2013 Sep 23;9(18):3138-46
pubmed: 23625779
Leuk Res. 2009 Nov;33(11):1440-7
pubmed: 19595459
Biomaterials. 2017 Nov;146:136-145
pubmed: 28918263
Nanomedicine. 2017 May;13(4):1389-1398
pubmed: 28137659
Expert Opin Drug Deliv. 2016;13(4):547-59
pubmed: 26735861
Adv Drug Deliv Rev. 2008 Aug 17;60(11):1289-1306
pubmed: 18501989
Semin Cancer Biol. 2014 Oct;28:3-13
pubmed: 24769058
Int Rev Cell Mol Biol. 2012;295:139-74
pubmed: 22449489
ACS Nano. 2013 Jun 25;7(6):5091-101
pubmed: 23705969
J Biol Chem. 1998 Mar 27;273(13):7507-11
pubmed: 9516451
Int J Nanomedicine. 2020 Feb 05;15:675-704
pubmed: 32103936
Mol Cell. 2019 Jan 17;73(2):354-363.e3
pubmed: 30581146
Nano Converg. 2019 Jul 15;6(1):23
pubmed: 31304563
Ther Deliv. 2012 Nov;3(11):1263-7
pubmed: 23259247
Angew Chem Int Ed Engl. 2018 Apr 23;57(18):4902-4906
pubmed: 29488312
J Am Chem Soc. 2015 Mar 4;137(8):3017-23
pubmed: 25662739
Int J Mol Sci. 2019 Sep 04;20(18):
pubmed: 31487938
ACS Nano. 2015 Nov 24;9(11):11064-74
pubmed: 26456218
Toxicol Sci. 2016 Apr;150(2):473-87
pubmed: 26801583
Int J Mol Sci. 2018 Mar 07;19(3):
pubmed: 29518914
Anal Chem. 2018 Mar 20;90(6):4188-4195
pubmed: 29504391
Cell Mol Life Sci. 2014 Nov;71(21):4259-73
pubmed: 24740795
Cancer Lett. 2011 Dec 8;311(2):131-40
pubmed: 21840122
Nat Nanotechnol. 2017 Jan;12(1):81-89
pubmed: 27618255
Biomaterials. 2018 Feb;154:24-33
pubmed: 29120816
Int J Nanomedicine. 2015 Aug 26;10:5435-45
pubmed: 26346915
Adv Mater. 2015 Jan 14;27(2):215-22
pubmed: 25423915
ACS Cent Sci. 2017 Aug 23;3(8):839-846
pubmed: 28852697
ACS Nano. 2009 Jun 23;3(6):1335-44
pubmed: 19489561